Forest Gets Untitled Letter After Reps Downplay Weight-Loss Risks

Washington Drug Letter
Forest Laboratories has been hit with an untitled letter after two of its sales reps implied that weight loss while using Daliresp tablets — listed as an adverse reaction — could be beneficial for overweight chronic obstructive pulmonary disease (COPD) patients.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00